Goerwihl, Germany

Michael Hackebeil

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Cis Biopharma Ag. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michael Hackebeil: Innovator in Biocompatible Drug Delivery Systems

Introduction

Michael Hackebeil is a notable inventor based in Goerwihl, Germany. He has made significant contributions to the field of biocompatible drug delivery systems. His innovative work focuses on the development of polymeric drug carriers that enhance the delivery of active agents.

Latest Patents

Michael Hackebeil holds a patent for "Biocompatible polymeric drug carriers for delivering active agents." This patent describes a method for delivering multiple copies of a payload molecule, such as an active agent or a chelating agent. The delivery system utilizes a biocompatible copolymer that is functionalized with side chain-linked amino acids. These amino acids are modified at their alpha-amino group with a reactive azide moiety, allowing for the coupling of payload molecules to the copolymer. Additionally, the copolymer can be further functionalized to include a targeting moiety specific to certain cell or tissue types. He has 1 patent in this area.

Career Highlights

Michael Hackebeil is associated with Cis Biopharma AG, where he continues to advance his research and development efforts. His work is pivotal in creating more effective drug delivery systems that can improve patient outcomes.

Collaborations

Michael collaborates with esteemed colleagues, including Davide Panighetti and Christophe Thommen. Their combined expertise contributes to the innovative projects at Cis Biopharma AG.

Conclusion

Michael Hackebeil's contributions to biocompatible drug delivery systems exemplify the importance of innovation in the medical field. His work not only enhances the efficacy of drug delivery but also paves the way for future advancements in biopharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…